Evidence map›Paper›PMID 39665388›Full record

ArticlemAbs

Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the

Dale O Starkie, Charles Arber, Terry Baker, Daniel J Lightwood, Selina Wray

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dale O StarkieAntibody Discovery and Optimization, UCB Pharma, Slough, Berkshire, UK.ORCID 0009-0007-0295-5758
Charles ArberDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0002-9743-8134
Terry BakerAntibody Discovery and Optimization, UCB Pharma, Slough, Berkshire, UK.
Daniel J LightwoodAntibody Discovery and Optimization, UCB Pharma, Slough, Berkshire, UK.ORCID 0000-0003-1433-7459
Selina WrayDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0003-3062-7050

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microtubule-associated protein tau is inextricably linked to a group of clinically diverse neurodegenerative diseases termed tauopathies. The ratio balance of the major tau splicing isoform groups (3 R- and 4 R-tau) is critical in maintaining healthy neurons. An imbalance causing excess 4 R tau is associated with diseases such as progressive supranuclear palsy and frontotemporal dementia. The mechanisms by which increased 4 R results in neuronal dysfunction and neurodegeneration are not fully understood, and progress has been limited partly by a lack of suitable tools to investigate tau isoform imbalance. This work generated novel 3 R- and 4 R-specific antibody tools and 4 R-tau degrading intracellular antibody fragment "degrabodies". These were used to probe the molecular mechanisms of excess 4 R-tau in disease-mutant induced pluripotent stem cell-derived neurons. For the first time, we demonstrate a causative link between excess 4 R-tau and mitochondrial membrane hyperpolarization with wide-ranging potential for elucidating novel therapeutic approaches to treat neurodegenerative disease.

Indexed as

Induced Pluripotent Stem CellsMutationNeuronstau ProteinsHumansMitochondrial MembranesProtein IsoformsProteolysisTauopathiesMAPT protein, humanProtein Isoformstau ProteinsAntibody Discoverydegrabodiesdegrading antibody fragmentsintracellular antibody technologiesiPSC-derrived neuronstargeted protein degradationtau

Identifiers

PMID39665388
PMCPMC11790244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.